“Autoimmune diseases impose a substantial ... sixth collaboration for the $7 billion biobucks, 10-program collaboration between Pfizer and Flagship that was first announced in 2023.

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for autoimmune diseases. The collaboration between Pfizer and Pioneering Medicines, ...

Collaboration leverages ... and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

This enables it to selectively deplete B cells and dampen autoimmune and inflammatory processes, potentially offering improved benefit and safety versus other therapeutic approaches targeting B cells.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

“This collaboration represents a strategic expansion of Boehringer’s pipeline portfolio in autoimmune and inflammatory diseases, an area that remains challenging and where people living with ...